Cargando…

Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease

Several molecular technologies aimed at regulating gene expression that have been recently developed as a strategy to combat inflammatory and neoplastic diseases. Among these, antisense technology is a specific, rapid, and potentially high-throughput approach for inhibiting gene expression through r...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Fusco, Davide, Dinallo, Vincenzo, Marafini, Irene, Figliuzzi, Michele M., Romano, Barbara, Monteleone, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450224/
https://www.ncbi.nlm.nih.gov/pubmed/30983999
http://dx.doi.org/10.3389/fphar.2019.00305
_version_ 1783408998089752576
author Di Fusco, Davide
Dinallo, Vincenzo
Marafini, Irene
Figliuzzi, Michele M.
Romano, Barbara
Monteleone, Giovanni
author_facet Di Fusco, Davide
Dinallo, Vincenzo
Marafini, Irene
Figliuzzi, Michele M.
Romano, Barbara
Monteleone, Giovanni
author_sort Di Fusco, Davide
collection PubMed
description Several molecular technologies aimed at regulating gene expression that have been recently developed as a strategy to combat inflammatory and neoplastic diseases. Among these, antisense technology is a specific, rapid, and potentially high-throughput approach for inhibiting gene expression through recognition of cellular RNAs. Advances in the understanding of the molecular mechanisms that drive tissue damage in different inflammatory diseases, including Crohn’s disease (CD) and ulcerative colitis (UC), the two major inflammatory bowel diseases (IBDs) in humans, have facilitated the identification of novel druggable targets and offered interesting therapeutic perspectives for the treatment of patients. This short review provides a comprehensive understanding of the basic concepts underlying the mechanism of action of the oligonucleotide therapeutics, and summarizes the available pre-clinical and clinical data for oligonucleotide-based therapy in IBD.
format Online
Article
Text
id pubmed-6450224
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64502242019-04-12 Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease Di Fusco, Davide Dinallo, Vincenzo Marafini, Irene Figliuzzi, Michele M. Romano, Barbara Monteleone, Giovanni Front Pharmacol Pharmacology Several molecular technologies aimed at regulating gene expression that have been recently developed as a strategy to combat inflammatory and neoplastic diseases. Among these, antisense technology is a specific, rapid, and potentially high-throughput approach for inhibiting gene expression through recognition of cellular RNAs. Advances in the understanding of the molecular mechanisms that drive tissue damage in different inflammatory diseases, including Crohn’s disease (CD) and ulcerative colitis (UC), the two major inflammatory bowel diseases (IBDs) in humans, have facilitated the identification of novel druggable targets and offered interesting therapeutic perspectives for the treatment of patients. This short review provides a comprehensive understanding of the basic concepts underlying the mechanism of action of the oligonucleotide therapeutics, and summarizes the available pre-clinical and clinical data for oligonucleotide-based therapy in IBD. Frontiers Media S.A. 2019-03-29 /pmc/articles/PMC6450224/ /pubmed/30983999 http://dx.doi.org/10.3389/fphar.2019.00305 Text en Copyright © 2019 Di Fusco, Dinallo, Marafini, Figliuzzi, Romano and Monteleone. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Di Fusco, Davide
Dinallo, Vincenzo
Marafini, Irene
Figliuzzi, Michele M.
Romano, Barbara
Monteleone, Giovanni
Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
title Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
title_full Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
title_fullStr Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
title_full_unstemmed Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
title_short Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
title_sort antisense oligonucleotide: basic concepts and therapeutic application in inflammatory bowel disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450224/
https://www.ncbi.nlm.nih.gov/pubmed/30983999
http://dx.doi.org/10.3389/fphar.2019.00305
work_keys_str_mv AT difuscodavide antisenseoligonucleotidebasicconceptsandtherapeuticapplicationininflammatoryboweldisease
AT dinallovincenzo antisenseoligonucleotidebasicconceptsandtherapeuticapplicationininflammatoryboweldisease
AT marafiniirene antisenseoligonucleotidebasicconceptsandtherapeuticapplicationininflammatoryboweldisease
AT figliuzzimichelem antisenseoligonucleotidebasicconceptsandtherapeuticapplicationininflammatoryboweldisease
AT romanobarbara antisenseoligonucleotidebasicconceptsandtherapeuticapplicationininflammatoryboweldisease
AT monteleonegiovanni antisenseoligonucleotidebasicconceptsandtherapeuticapplicationininflammatoryboweldisease